Results 181 to 190 of about 632,116 (307)

Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley   +1 more source

Cardiometabolic regulation by adipocyte-derived leptin and the brain melanocortin system. [PDF]

open access: yesClin Sci (Lond)
Hall JE   +6 more
europepmc   +1 more source

Serum Lipidomics Profiling Identify Novel Biomarkers of Distal Symmetrical Polyneuropathy in Type 1 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Distal symmetrical polyneuropathy (DSPN) is a common complication of type 1 diabetes (T1D), yet validated biomarkers for early detection or prognosis are lacking. Metabolic disturbances driven by chronic hyperglycemia and dyslipidemia contribute to DSPN development and progression.
Tik Muk   +18 more
wiley   +1 more source

Evaluating Whole Fruit Feijoa Powder for Type 2 Diabetes Risk Prevention: A Randomised Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Low energy diets (LEDs) are effective for body weight (BW) loss and improvement of type 2 diabetes (T2D) risk biomarkers. Emerging evidence suggests that whole fruit feijoa powder, rich in polyphenols and abscisic acid, may further support T2D prevention.
I. A. Mohamed   +6 more
wiley   +1 more source

A Biweekly GLP‐1R Agonist Designed With Drug‐Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To develop a next‐generation, longer‐acting, more‐clinical‐benefits agonist to achieve sustained efficacy with improved tolerability. Methods CT130 was designed from semaglutide. Binding affinity was validated via molecular dynamics and cellular assays.
Wei Ding   +4 more
wiley   +1 more source

Non‐Invasive Fibrosis Testing in Adults With Obesity and MASLD: A Systematic Review and Meta‐Analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Adults with obesity are at increased risk of metabolic dysfunction‐associated steatotic liver disease (MASLD)‐related fibrosis, but the diagnostic performance of non‐invasive tests (NITs) in this population remains uncertain. This meta‐analysis evaluated NITs for detecting significant (≥F2) and advanced (≥F3) fibrosis in adults with ...
Patricia M. Ortega   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy